1 Broadway # 14, Cambridge, MA 02142
One compelling example is fumagillin-class small molecules, which have shown clinical activity in both cancer and obese patients but have also caused toxicities. That gave us a starting point for our drug development program.
It’s nothing new for a pharma to pick up a discarded asset and then develop it for a different patient population or indication. SynDevRx, however, has taken a different tack. Through our proprietary polymer-drug conjugation approach, we’ve worked to enhance the efficacy of fumagillin-class drugs in cancer patients while reducing the toxic effects.
In 2015 our co-founders saw that no one in the pharmaceutical industry was focusing on the unique needs of cancer patients who are also overweight or obese. So they directed our lead compound, SDX-7320 — which had shown activity in both metabolic and cancer animal models — toward this “metabo-oncologic” patient population.
We’ve moved our lead compound from discovery and early chemistry through patenting and into late-stage Phase 1 trials at costs well below the industry norm.
The SynDevRx team includes an impressive roster of well-known clinical oncologists, leaders in academic research, professors from premier institutions and experienced drug development professionals. Many came here with direct, hands-on research and clinical experience with fumagillin-based small molecules. In fact, Don Ingber, M.D., Ph.D., a member of our Scientific Advisory Board, actually discovered fumagillin-class compounds in 1985.
Every day, we put our heart and soul into our business, never forgetting that clinical success would mean transforming cancer treatment as we know it. That’s a powerful motivation, and we won’t stop until we get there.